Vaccines effective against most SARS-CoV-2 variants

Two of the commonly used coronavirus vaccines provide protection against multiple variants of the virus that causes COVID-19, including the highly infectious Delta variant, a new Yale study has found.

The findings, published Oct. 11 in the journal Nature, also show at those infected with the virus prior to vaccination exhibit a more robust immune response to all variants than those who were uninfected and fully vaccinated.

The results come as an increase in so-called "breakthrough" infections caused by the Delta variant among vaccinated individuals continues to raise questions about whether the vaccines offer broad protection against newly arising variants.

According to the researchers, the Moderna and Pfizer-BioNTech vaccines do bolster the immune system’s response to infection.

"Vaccines induce high levels of antibodies against Delta and most variants," said Akiko Iwasaki, the Waldemar Von Zedtwitz Professor of Immunobiology and co-corresponding author of the paper. "And two shots are better than one."

In addition, the results suggest that booster shots can be effective in warding off SARS-CoV-2, the authors say.

For the study, a research team led by Iwasaki and two co-corresponding authors - Nathan Grubaugh, associate professor of epidemiology at Yale, and Saad Omer, director of the Yale Institute for Global Health - collected blood samples from 40 healthcare workers in the Yale New Haven Health System between November, 2020 and January, 2021 before they had received vaccinations. In the following weeks, they periodically took additional samples after the volunteers received their first and second doses of the Moderna or Pfizer-BioNTech mRNA vaccines.

The researchers then exposed the volunteers' blood samples to 16 different SARS-COV-2 variants, including the Delta variant, the most predominate strain circulating in the United States, and then measured antibody and T cell response to each of the variants. (None of the volunteers was exposed to the virus.)

The researchers found evidence of enhanced immune system response in all blood samples, although the strength of response varied by variant and by individual. The immune system response to the Delta variant in the blood of all volunteers was generally robust - and even stronger in samples collected after the individuals' second shots.

The breakthrough cases attributed to the Delta variant are unlikely to arise from a failure of vaccines, Iwasaki said. Rather, they likely stem from the extremely infectious nature of the Delta variant, which can overcome the immune defense, she said.

Other studies have also shown that vaccinated individuals tend to have less severe infections.

"The Delta variant is more infectious than earlier variants," Grubaugh added. "The high transmissibility of the variant, not its escape from our vaccine-induced immune response, best explains infections among the vaccinated."

The researchers also divided healthcare volunteers into two groups: those who had been infected by COVID-19 prior to vaccination and those who had not. The immune response of those infected prior to vaccination was more robust than for those who never been infected.

"Recovering from an initial infection is like getting a first vaccine shot," Iwasaki said.

A booster shot among those vaccinated could have a similar effect, increasing presence of antibodies and T cells that protect against infections, she said.

Yale's Carolina Lucas, Chantal Vogels, and Inci Yildirim are co-lead authors of the study.

Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gelhausen JR, Campbell M, Silva J, Tabachikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J; Yale SARS-CoV-2 Genomic Surveillance Initiative, Shaw AC, Ko AI, Omer SB, Grubaugh ND, Iwasaki A.
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Nature. 2021 Oct 11. doi: 10.1038/s41586-021-04085-y

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...